Prolonged Bleeding: Labs, Causes, and Next Steps

What Qualifies as Prolonged Bleeding

Bleeding is considered prolonged when it exceeds the expected duration for a given clinical scenario. A nosebleed lasting more than 20 minutes, a skin laceration still oozing after 10 minutes of direct pressure, or menstrual flow persisting beyond 7 days all meet the threshold. The International Society on Thrombosis and Haemostasis (ISTH) developed a standardized bleeding assessment tool (BAT) that quantifies bleeding severity across multiple domains, assigning scores that help clinicians distinguish normal variation from pathology [1].

Context matters. A single prolonged nosebleed during dry winter air differs from recurrent gum bleeding plus easy bruising plus heavy periods. The BAT captures this pattern recognition by scoring 14 different bleeding symptoms on a 0-to-4 scale. An abnormal score (greater than or equal to 4 in adult females, greater than or equal to 3 in adult males) warrants formal hematologic evaluation [1]. Postoperative bleeding that requires re-exploration or transfusion also qualifies, even if it occurs only once. Your physician should ask about family history, because inherited bleeding disorders follow predictable inheritance patterns and a positive family history raises pre-test probability substantially.

Common Causes of Prolonged Bleeding

The differential diagnosis splits into three broad categories: coagulation factor deficiencies, platelet disorders, and vascular or structural problems. Each one produces a distinct bleeding pattern that guides the workup.

Coagulation factor deficiencies include hemophilia A (factor VIII deficiency), hemophilia B (factor IX deficiency), and rarer deficiencies of factors II, V, VII, X, XI, or XIII. Hemophilia A occurs in approximately 1 in 5,000 male births [2]. These conditions typically produce deep tissue bleeding, hemarthrosis, and delayed surgical bleeding rather than superficial mucosal oozing.

Platelet disorders encompass both quantitative problems (low platelet count, or thrombocytopenia) and qualitative problems (normal count but impaired function). Von Willebrand disease (VWD) sits at the intersection of platelet adhesion and coagulation, because von Willebrand factor (VWF) both mediates platelet binding to injured vessels and serves as the carrier protein for factor VIII. A 2016 review in the New England Journal of Medicine noted that "von Willebrand's disease is the most common inherited bleeding disorder, with a prevalence of symptomatic disease of approximately 1 in 1,000 individuals" [3].

Structural and vascular causes include uterine fibroids, endometrial polyps, arteriovenous malformations, hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome), and acquired vascular fragility from aging or corticosteroid use. These require imaging or endoscopic evaluation rather than coagulation labs alone.

The First-Line Lab Panel for Prolonged Bleeding

Every evaluation begins with a core set of tests. These five studies cost relatively little and cover the most common diagnoses.

Complete blood count (CBC) with differential establishes your baseline hemoglobin, hematocrit, and platelet count. A platelet count below 150,000/µL defines thrombocytopenia. Severe thrombocytopenia (below 20,000/µL) can cause spontaneous mucosal bleeding [4]. The mean platelet volume (MPV) on the CBC also provides clues: large platelets suggest peripheral destruction or inherited macrothrombocytopenia, while small platelets point toward Wiskott-Aldrich syndrome.

Prothrombin time (PT) and INR measure the extrinsic and common coagulation pathways (factors VII, X, V, II, and fibrinogen). A prolonged PT with normal aPTT narrows the differential to factor VII deficiency, mild liver disease, or vitamin K deficiency [5].

Activated partial thromboplastin time (aPTT) evaluates the intrinsic pathway (factors XII, XI, IX, VIII) plus the common pathway. Isolated aPTT prolongation in a bleeding patient raises suspicion for hemophilia A or B, while combined PT and aPTT prolongation suggests common pathway involvement, DIC, liver failure, or supratherapeutic anticoagulation [5].

Fibrinogen level completes the screening panel. Normal fibrinogen ranges from 200 to 400 mg/dL. Levels below 100 mg/dL increase bleeding risk significantly, particularly in DIC, massive transfusion scenarios, or rare inherited hypofibrinogenemia.

Peripheral blood smear provides morphologic data the automated CBC may miss: schistocytes (suggesting microangiopathic hemolytic anemia or DIC), platelet clumping (causing pseudothrombocytopenia), or abnormal white cells (raising concern for leukemia-related bleeding).

Second-Tier Testing: When the Basics Come Back Normal

A normal CBC, PT, aPTT, and fibrinogen do not rule out a bleeding disorder. Von Willebrand disease often presents with entirely normal screening labs, because VWF levels fluctuate with stress, estrogen exposure, blood type, and inflammation. According to National Heart, Lung, and Blood Institute (NHLBI) guidelines, "a single normal VWF level does not exclude the diagnosis of VWD if clinical suspicion is high" [6].

The von Willebrand panel includes three tests: VWF antigen (VWF:Ag), VWF activity (VWF:RCo or VWF:GPIbM), and factor VIII activity. Type 1 VWD shows proportionally reduced antigen and activity. Type 2 variants show disproportionate reductions (activity much lower than antigen), and type 3 VWD shows virtually absent VWF. Roughly 70 to 80% of VWD cases are type 1 [3].

Platelet function testing via PFA-100 (platelet function analyzer) or light transmission aggregometry can identify qualitative platelet defects missed by a normal platelet count. The PFA-100 measures closure time of a collagen/epinephrine and collagen/ADP aperture; prolonged closure times suggest VWD or primary platelet dysfunction [7]. Light transmission aggregometry remains the gold standard for diagnosing specific platelet function defects like Glanzmann thrombasthenia or Bernard-Soulier syndrome, though it requires specialized laboratories.

Factor XIII activity deserves mention because factor XIII deficiency does not prolong the PT or aPTT. Patients with this rare condition bleed normally from initial wounds but develop delayed bleeding, poor wound healing, and recurrent miscarriage. A factor XIII activity level below 5% is diagnostic [5].

Thrombin time and reptilase time help differentiate heparin contamination (prolonged thrombin time, normal reptilase time) from fibrinogen disorders (both prolonged).

Gynecological Evaluation for Prolonged Menstrual Bleeding

Abnormal uterine bleeding (AUB) affects an estimated 10 to 30% of reproductive-age women and is the most common reason for gynecologic referral [8]. The FIGO PALM-COEIN classification system organizes causes into structural (Polyp, Adenomyosis, Leiomyoma, Malignancy) and non-structural (Coagulopathy, Ovulatory dysfunction, Endometrial, Iatrogenic, Not yet classified) categories [8].

The American College of Obstetricians and Gynecologists (ACOG) recommends that all adolescents and women presenting with heavy menstrual bleeding undergo screening for VWD and other bleeding disorders, stating in Practice Bulletin No. 128 that "initial laboratory evaluation should include a complete blood count, and testing for von Willebrand disease should be considered" [9]. This recommendation reflects data showing that roughly 13% of women with heavy menstrual bleeding have an underlying bleeding disorder, compared to roughly 1% in the general female population [10].

Transvaginal ultrasound is the first-line imaging study. It identifies fibroids, endometrial polyps, and endometrial thickness abnormalities with sensitivity exceeding 90% for intracavitary lesions when performed with saline infusion sonohysterography [8]. Endometrial biopsy is indicated for women over 45 with AUB, or for younger women with risk factors for endometrial hyperplasia (obesity, chronic anovulation, tamoxifen use, or family history of endometrial or colorectal cancer).

Thyroid function testing (TSH) is standard in the AUB workup. Both hypothyroidism and hyperthyroidism can alter menstrual patterns. A serum pregnancy test should be performed in any reproductive-age woman, because pregnancy complications (ectopic pregnancy, threatened miscarriage, gestational trophoblastic disease) can present as prolonged or irregular bleeding.

Medication-Induced Prolonged Bleeding

Medications are among the most common acquired causes of prolonged bleeding, and a careful medication reconciliation is required before pursuing expensive hematologic testing.

Anticoagulants are the most obvious culprits. Warfarin, with its narrow therapeutic index, causes major bleeding in approximately 1 to 3% of patients annually even with careful INR monitoring [11]. Direct oral anticoagulants (DOACs) like rivaroxaban, apixaban, edoxaban, and dabigatran carry somewhat lower major bleeding rates (approximately 2 to 3% per year in atrial fibrillation trials), but they still cause clinically significant prolonged bleeding from wounds, gums, and the GI tract [11].

Antiplatelet agents including aspirin, clopidogrel, prasugrel, and ticagrelor impair platelet function for the lifespan of the platelet (7 to 10 days for aspirin, shorter for P2Y12 inhibitors upon discontinuation). Dual antiplatelet therapy following coronary stenting increases bleeding risk roughly twofold compared to aspirin alone [12].

NSAIDs (ibuprofen, naproxen, diclofenac) reversibly inhibit cyclooxygenase and impair platelet aggregation for the duration of drug exposure. Regular NSAID use compounds bleeding risk when combined with anticoagulants or antiplatelet agents.

SSRIs and SNRIs reduce platelet serotonin content, impairing the secondary platelet aggregation response. A meta-analysis of 42 observational studies found that SSRI use increased the risk of upper GI bleeding by approximately 55% (pooled OR 1.55, 95% CI 1.35-1.78) [13]. The effect is dose-dependent and magnified by concurrent NSAID or anticoagulant use.

Herbal supplements including ginkgo biloba, garlic extract, ginseng, and fish oil at high doses (above 3 g/day of EPA+DHA) can impair hemostasis. Patients often do not volunteer supplement use, so specific questioning is necessary.

Treatment Approaches Based on Underlying Cause

Treatment follows diagnosis. There is no single "prolonged bleeding medication" because the cause dictates the intervention.

Von Willebrand disease type 1 responds well to desmopressin (DDAVP), which stimulates release of stored VWF from endothelial cells. A 0.3 µg/kg intravenous dose typically raises VWF levels 3 to 5 fold within 30 to 60 minutes [3]. A desmopressin challenge test before planned surgery confirms individual response. Type 2B VWD is a contraindication to desmopressin because it can worsen thrombocytopenia. Types 2 and 3 VWD generally require VWF-containing factor concentrates (Humate-P, Vonvendi) [6].

Hemophilia treatment depends on severity. Mild hemophilia A may respond to desmopressin. Moderate to severe hemophilia A requires factor VIII replacement (recombinant or plasma-derived) or emicizumab, a bispecific antibody that bridges factors IXa and X to mimic the function of factor VIII. The HAVEN 1 trial (N=109) demonstrated that emicizumab prophylaxis reduced annualized bleeding rate by 87% compared to no prophylaxis in hemophilia A patients with inhibitors [14].

Thrombocytopenia treatment varies by mechanism. Immune thrombocytopenia (ITP) may respond to corticosteroids (prednisone 1 mg/kg/day), intravenous immunoglobulin (IVIG), thrombopoietin receptor agonists (eltrombopag, romiplostim), or rituximab. Drug-induced thrombocytopenia resolves with discontinuation of the offending agent.

Abnormal uterine bleeding from structural causes may require procedural intervention. Hysteroscopic polypectomy or myomectomy treats polyps and submucosal fibroids. The LNG-IUS (levonorgestrel intrauterine system, Mirena) reduces menstrual blood loss by approximately 90% at 12 months and is recommended by NICE as first-line treatment for heavy menstrual bleeding in the absence of structural pathology [15]. Combined oral contraceptives and oral progestins (norethindrone acetate, medroxyprogesterone acetate) are alternative hormonal options.

Tranexamic acid (1 g orally three times daily during menses, or 1 g IV for acute non-surgical bleeding) inhibits fibrinolysis and reduces bleeding across multiple etiologies. It does not correct the underlying cause but provides effective symptom control while the workup proceeds.

When Prolonged Bleeding Requires Emergency Evaluation

Certain presentations demand immediate evaluation, not a scheduled outpatient workup.

Seek emergency care for: active bleeding with lightheadedness, heart rate above 100 bpm, or systolic blood pressure below 90 mmHg. These vital sign changes suggest hemorrhagic shock. A hemoglobin below 7 g/dL with ongoing bleeding typically warrants red blood cell transfusion per restrictive transfusion guidelines [16]. Bleeding into a closed space (intracranial, retroperitoneal, compartmental) is life-threatening regardless of volume. New-onset petechiae covering multiple body regions with a platelet count below 10,000/µL raises concern for thrombotic thrombocytopenic purpura (TTP) or acute leukemia, both of which require same-day hematologic consultation.

Postpartum hemorrhage, defined as blood loss exceeding 1,000 mL or bleeding accompanied by hemodynamic instability, affects roughly 3 to 5% of deliveries and remains a leading cause of maternal morbidity worldwide [17]. It requires a distinct protocol (uterine massage, uterotonics, tranexamic acid within 3 hours of delivery per the WOMAN trial, and possible surgical intervention).

Building a Diagnostic Timeline With Your Care Team

A structured approach prevents both missed diagnoses and unnecessary testing. Start with the first-line panel (CBC, PT/INR, aPTT, fibrinogen, smear) at your initial visit. If results are normal but clinical suspicion persists, request second-tier studies (VWF panel, PFA-100, factor XIII) within 2 to 4 weeks. For menstrual bleeding, coordinate gynecologic imaging and endometrial sampling concurrently with hematologic testing to run both evaluations in parallel.

Keep a bleeding diary before your appointments. Record the date, location, duration, and estimated volume of each bleeding episode. Quantify menstrual flow using a pictorial blood loss assessment chart (PBAC), where a score above 100 per cycle correlates with measured blood loss exceeding 80 mL [8]. Bring a complete medication and supplement list. Results from a VWF panel drawn during an acute illness or pregnancy may be falsely normal because VWF is an acute-phase reactant, so repeat testing during a baseline health state if the first result is borderline.

The median time from symptom onset to VWD diagnosis exceeds 10 years in women, largely because heavy periods are normalized culturally and clinically [10]. If your screening labs return normal but your ISTH-BAT score is elevated, ask specifically for a hematology referral rather than accepting reassurance.